Fiche centre
Visionary Investigators Network
Miami — United States
Essais liés10clinical trials
VilleMiamilocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05543681
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| XEN1101 | Épilepsie | Phase 2 | NCT03796962 | X-TOLE — A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | ACTIVE_NOT_RECRUITING |
| SPN-817 | Épilepsie | Phase 2 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | RECRUITING |
| IGC-AD1-Active | Alzheimer | Phase 2 | NCT05543681 | CALMA — Clinical Trial on Agitation in Alzheimer's Dementia | ACTIVE_NOT_RECRUITING |
| ACP-204 | Alzheimer | Phase 2/3 | NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 4 | NCT06909214 | ADAPT-EARLY — A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Galcanezumab | Migraine | Phase 4 | NCT05127486 | CHALLENGE-MIG — A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine | COMPLETED |
| Empasiprubart IV | Myasthénie | Phase 2 | NCT07673627 | ADAPT Forward2 — ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING |
| Efgartigimod IV | Myasthénie | À vérifier | NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Efgartigimod IV | Myasthénie | Phase 2 | NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | RECRUITING |